JOINT FILING AGREEMENTJoint Filing Agreement • February 4th, 2022 • Impactive Capital LP • In vitro & in vivo diagnostic substances
Contract Type FiledFebruary 4th, 2022 Company IndustryIn accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Shares, no par value, of Meridian Bioscience, Inc., an Ohio corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.